Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES M WINKLEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1932120011
CMS profile
268687
Location
LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$200,036.00

517 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 11; records 51–100 of 517 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES M WINKLEY

NPI 1932120011 · CMS profile ID 268687

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 11; records 51–100 of 517 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932120011?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES M WINKLEY, NPI 1932120011, CMS profile ID 268687. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 11; records 51–100 of 517 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932120011?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMES M WINKLEY, NPI 1932120011, CMS profile ID 268687. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 11; records 51–100 of 517 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932120011?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMES M WINKLEY, NPI 1932120011, CMS profile ID 268687, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 11; records 51–100 of 517 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932120011?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

517 matching records · $200,036.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 517 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 517.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $97.2111/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240436871 CMS
Amgen Inc. $146.2111/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447638 CMS
GENZYME CORPORATION $25.6211/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233306244 CMS
Grifols USA, LLC $16.4311/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249572281 CMS
PFIZER INC. $1.7811/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229369782 CMS
Vanda Pharmaceuticals Inc. $20.0311/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233014702 CMS
ARGENX US, INC. $428.5311/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1240436863 CMS
ARGENX US, INC. $125.0011/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240437198 CMS
ARGENX US, INC. $60.0011/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240437212 CMS
ARGENX US, INC. $50.0011/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240437260 CMS
ARGENX US, INC. $75.0011/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240437278 CMS
ABBVIE INC. $6.9511/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769450 CMS
Novartis Pharmaceuticals Corporation $20.2211/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200386228 CMS
ARGENX US, INC. $20.6311/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240451105 CMS
Amgen Inc. $2,750.0011/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226874338 CMS
Amgen Inc. $22.8411/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447665 CMS
TG Therapeutics, Inc. $465.0011/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226259333 CMS
Amgen Inc. $3,300.0011/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226894955 CMS
ABBVIE INC. $7.9711/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769446 CMS
Celgene Corporation $11.1711/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184558316 CMS
Alexion Pharmaceuticals, Inc. $23.7311/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202926206 CMS
Biogen, Inc. $26.1811/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208368444 CMS
Janssen Biotech, Inc. $99.9911/06/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174508648 CMS
PFIZER INC. $1.6011/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229544673 CMS
Amgen Inc. $35.2111/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447669 CMS
Amgen Inc. $122.2511/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447672 CMS
Amgen Inc. $35.2111/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447703 CMS
Janssen Biotech, Inc. $21.3811/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174504536 CMS
Novartis Pharmaceuticals Corporation $27.5211/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200386226 CMS
Lundbeck LLC $19.7610/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251860253 CMS
Amgen Inc. $17.0210/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228447711 CMS
PFIZER INC. $1.6010/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229810361 CMS
ABBVIE INC. $20.4610/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769442 CMS
Teva Pharmaceuticals USA, Inc. $2,380.0010/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247287894 CMS
Biogen, Inc. $25.5210/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208307517 CMS
PFIZER INC. $24.0010/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229880991 CMS
Janssen Biotech, Inc. $2,498.0010/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174508340 CMS
ABBVIE INC. $7.1310/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769438 CMS
Janssen Biotech, Inc. $109.1810/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174514303 CMS
Neurocrine BioSciences, Inc. $25.9610/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243001862 CMS
Novartis Pharmaceuticals Corporation $5.5710/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200386224 CMS
Vanda Pharmaceuticals Inc. $19.7310/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233014700 CMS
Janssen Scientific Affairs, LLC $5.0010/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174167849 CMS
ABBVIE INC. $6.3910/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769434 CMS
Alexion Pharmaceuticals, Inc. $27.7910/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202916029 CMS
PFIZER INC. $3.8210/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229839929 CMS
UCB, Inc. $5.8410/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224425108 CMS
UCB, Inc. $18.1410/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224425110 CMS
ABBVIE INC. $5.9110/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769426 CMS
ABBVIE INC. $6.4810/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204769430 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137,747.50 335
PY2020 $119,317.56 229
PY2021 $73,506.90 277
PY2022 $96,714.68 302
PY2023 $60,534.58 349
PY2024 $119,471.81 393
PY2025 $200,036.00 517

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $125,070.77 35
PY2024 Principal investigator $190,067.91 54
PY2023 Principal investigator $214,699.88 57
PY2022 Principal investigator $125,791.17 18
PY2021 Principal investigator $137,057.81 43
PY2020 Principal investigator $162,295.66 55
PY2019 Recipient $12,027.04 7
PY2019 Principal investigator $186,391.56 66

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $8,711.00 11/06/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211541022
Principal investigator 1 Alexion Pharmaceuticals, Inc. $8,946.15 10/20/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185543314
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,126.00 10/15/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM, INC
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185543318
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540922
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540932
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540949
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540962
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540970
Principal investigator 1 Roche Products Limited $295.00 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540974
Principal investigator 1 Roche Products Limited $265.50 09/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540997
Principal investigator 1 Genentech, Inc. $8,711.00 09/19/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211541018
Principal investigator 1 Genentech, Inc. $2,791.00 09/18/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211541014
Principal investigator 1 GENZYME CORPORATION $1,500.00 08/18/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083177
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540927
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540936
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540941
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540945
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540952
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540956
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540966
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540980
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540984
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540989
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540993
Principal investigator 1 Roche Products Limited $295.00 07/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211541001
Principal investigator 1 Genentech, Inc. $5,388.00 06/25/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211541005
Principal investigator 1 Alexion Pharmaceuticals, Inc. $1,024.00 05/22/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185543316
Principal investigator 1 GENZYME CORPORATION $19,300.00 05/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226142508
Principal investigator 1 Genentech, Inc. $3,525.00 04/15/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211541009
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,562.40 01/31/2025 Non-covered Recipient Entity
BAPTIST PHYSICIANS LEXINGTON
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303897
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,532.72 01/16/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190294456
Principal investigator 1 GENZYME CORPORATION $15,938.00 01/13/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083116
Principal investigator 1 GENZYME CORPORATION $4,850.00 01/13/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226083121
Principal investigator 1 Roche Products Limited $295.00 01/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540914
Principal investigator 1 Roche Products Limited $295.00 01/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211540919